Preliminary results from a pilot study of avelumab, an anti-PD-L1 antibody, in 23 patients with relapsed TETs, which included 12 patients with thymoma, showed high pretreatment soluble PD-L1 levels in all patients compared with healthy donors [43]. The gene discussed is CD274; the disease is thymoma.